Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors

 April 10, 2026

BioPharma Dive

The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.

M&A / DealsOncologyRead full story

Post navigation

RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders →
← Bayer wins MHRA approval for Kerendia in heart failure

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com